Theravance Biopharma, Inc. (TBPH) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Theravance Biopharma, Inc. (TBPH) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Rick E Winningham (CEO) received $1,472,019 in reported total compensation@if($peoPaid !== null), with $7,662,197 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 166.76.
Frequently asked questions
Who is the CEO of TBPH and how much are they paid?
Rick E Winningham serves as CEO of Theravance Biopharma, Inc.. For fiscal year ending December 2025, reported total compensation was $1,472,019.
What is included in executive compensation?
SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
What is pay-versus-performance?
The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.